Pictilisib-Induced Resistance Is Mediated Through FOXO1-Dependent Activation of Receptor Tyrosine Kinases in Mucinous Colorectal Adenocarcinoma Cells

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2023 Aug 12

PMID 37569713

Authors

Murali R Kuracha

Venkatesh Govindarajan

Brian W Loggie

Martin Tobi

Benita L McVicker

Affiliations

Soon will be listed here.

Abstract

The phosphatidylinositol (PI3K)/AKT/mTOR axis represents an important therapeutic target to treat human cancers. A well-described downstream target of the PI3K pathway is the forkhead box O (FOXO) transcription factor family. FOXOs have been implicated in many cellular responses, including drug-induced resistance in cancer cells. However, FOXO-dependent acute phase resistance mediated by pictilisib, a potent small molecule PI3K inhibitor (PI3Ki), has not been studied. Here, we report that pictilisib-induced adaptive resistance is regulated by the FOXO-dependent rebound activity of receptor tyrosine kinases (RTKs) in mucinous colorectal adenocarcinoma (MCA) cells. The resistance mediated by PI3K inhibition involves the nuclear localization of FOXO and the altered expression of RTKs, including , , , , , and in MCA cells. Further, in the presence of FOXO siRNA, the pictilisib-induced feedback activation of RTK regulators (pERK and pAKT) was altered in MCA cells. Interestingly, the combinational treatment of pictilisib (Pi3Ki) and FOXO1i (AS1842856) synergistically reduced MCA cell viability and increased apoptosis. These results demonstrate that pictilisib used as a single agent induces acute resistance, partly through FOXO1 inhibition. Therefore, overcoming PI3Ki single-agent adaptive resistance by rational design of FOXO1 and PI3K inhibitor combinations could significantly enhance the therapeutic efficacy of PI3K-targeting drugs in MCA cells.

Citing Articles

The Innate Immune System Surveillance Biomarker p87 in African Americans and Caucasians with Small High-Grade Dysplastic Adenoma [SHiGDA] and Right-Sided Colon Mutations May Explain the Presence of Multiple Cancers Revealing an Important Minority....

Tobi M, Zhao X, Rodriquez R, Tobi Y, Ganguly T, Kuhn D Gastrointest Disord (Basel). 2024; 6(2):497-512.

PMID: 39507544 PMC: 11539196. DOI: 10.3390/gidisord6020034.

Experimental Verification of Erchen Decoction Plus Huiyanzhuyu Decoction in the Treatment of Laryngeal Squamous Cell Carcinoma Based on Network Pharmacology.

Tan X, Luo Q, Hua Y, Zhou S, Peng G, Zhu R Integr Cancer Ther. 2024; 23:15347354241259182.

PMID: 38845538 PMC: 11159533. DOI: 10.1177/15347354241259182.

Haider S, Chakraborty S, Chowdhury G, Chakrabarty A ACS Pharmacol Transl Sci. 2024; 7(5):1237-1251.

PMID: 38751638 PMC: 11091984. DOI: 10.1021/acsptsci.3c00279.

Novel Therapeutic Approaches for Colorectal Cancer Treatment.

Papavassiliou A, Delle Cave D Int J Mol Sci. 2024; 25(4).

PMID: 38396903 PMC: 10889277. DOI: 10.3390/ijms25042228.

References

Kajihara T, Jones M, Fusi L, Takano M, Feroze-Zaidi F, Pirianov G . Differential expression of FOXO1 and FOXO3a confers resistance to oxidative cell death upon endometrial decidualization. Mol Endocrinol. 2006; 20(10):2444-55. DOI: 10.1210/me.2006-0118. View

Hui R, Francis R, Guest S, Costa J, Gomes A, Myatt S . Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells. Mol Cancer Ther. 2008; 7(3):670-8. DOI: 10.1158/1535-7163.MCT-07-0397. View

Pan C, Jin X, Zhao Y, Pan Y, Yang J, Karnes R . AKT-phosphorylated FOXO1 suppresses ERK activation and chemoresistance by disrupting IQGAP1-MAPK interaction. EMBO J. 2017; 36(8):995-1010. PMC: 5391142. DOI: 10.15252/embj.201695534. View

Catalano V, Loupakis F, Graziano F, Torresi U, Bisonni R, Mari D . Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy. Br J Cancer. 2009; 100(6):881-7. PMC: 2661784. DOI: 10.1038/sj.bjc.6604955. View

Tan J, Yu Q . Molecular mechanisms of tumor resistance to PI3K-mTOR-targeted therapy. Chin J Cancer. 2013; 32(7):376-9. PMC: 3845604. DOI: 10.5732/cjc.012.10287. View

Symonds D, VICKERY A . Mucinous carcinoma of the colon and rectum. Cancer. 1976; 37(4):1891-1900. DOI: 10.1002/1097-0142(197604)37:4<1891::aid-cncr2820370439>3.0.co;2-z. View

Vivanco I, Sawyers C . The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002; 2(7):489-501. DOI: 10.1038/nrc839. View

Kops G, De Ruiter N, Powell D, Bos J, Burgering B . Direct control of the Forkhead transcription factor AFX by protein kinase B. Nature. 1999; 398(6728):630-4. DOI: 10.1038/19328. View

Goto T, Takano M, Albergaria A, Briese J, Pomeranz K, Cloke B . Mechanism and functional consequences of loss of FOXO1 expression in endometrioid endometrial cancer cells. Oncogene. 2007; 27(1):9-19. DOI: 10.1038/sj.onc.1210626. View

10.

Brunet A, Bonni A, Zigmond M, Lin M, Juo P, Hu L . Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 1999; 96(6):857-68. DOI: 10.1016/s0092-8674(00)80595-4. View

11.

Han C, Cho K, Choi H, Han H, Kang K . Role of FoxO1 activation in MDR1 expression in adriamycin-resistant breast cancer cells. Carcinogenesis. 2008; 29(9):1837-44. DOI: 10.1093/carcin/bgn092. View

12.

Matsumoto M, Han S, Kitamura T, Accili D . Dual role of transcription factor FoxO1 in controlling hepatic insulin sensitivity and lipid metabolism. J Clin Invest. 2006; 116(9):2464-72. PMC: 1533874. DOI: 10.1172/JCI27047. View

13.

Kuracha M, Thomas P, Loggie B, Govindarajan V . Bilateral blockade of MEK- and PI3K-mediated pathways downstream of mutant KRAS as a treatment approach for peritoneal mucinous malignancies. PLoS One. 2017; 12(6):e0179510. PMC: 5480880. DOI: 10.1371/journal.pone.0179510. View

14.

Mekenkamp L, Heesterbeek K, Koopman M, Tol J, Teerenstra S, Venderbosch S . Mucinous adenocarcinomas: poor prognosis in metastatic colorectal cancer. Eur J Cancer. 2012; 48(4):501-9. DOI: 10.1016/j.ejca.2011.12.004. View

15.

Rao P, Pang M, Qiao X, Yu H, Wang H, Yang Y . Promotion of β-catenin/Foxo1 signaling ameliorates renal interstitial fibrosis. Lab Invest. 2019; 99(11):1689-1701. DOI: 10.1038/s41374-019-0276-z. View

16.

Xia P, Chen J, Liu Y, Fletcher M, Jensen B, Cheng Z . Doxorubicin induces cardiomyocyte apoptosis and atrophy through cyclin-dependent kinase 2-mediated activation of forkhead box O1. J Biol Chem. 2020; 295(13):4265-4276. PMC: 7105316. DOI: 10.1074/jbc.RA119.011571. View

17.

Chou T, Talalay P . Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984; 22:27-55. DOI: 10.1016/0065-2571(84)90007-4. View

18.

Robertson B, Bonsal L, Chellaiah M . Regulation of Erk1/2 activation by osteopontin in PC3 human prostate cancer cells. Mol Cancer. 2010; 9:260. PMC: 3098013. DOI: 10.1186/1476-4598-9-260. View

19.

Sunters A, Fernandez de Mattos S, Stahl M, Brosens J, Zoumpoulidou G, Saunders C . FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines. J Biol Chem. 2003; 278(50):49795-805. DOI: 10.1074/jbc.M309523200. View

20.

Serra V, Scaltriti M, Prudkin L, Eichhorn P, Ibrahim Y, Chandarlapaty S . PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene. 2011; 30(22):2547-57. PMC: 3107390. DOI: 10.1038/onc.2010.626. View